Regeneron Pharmaceuticals, Inc. (REGN)

US — Healthcare Sector
Peers: VRTX  BMRN  SRPT  ALNY  BIIB  GILD  ILMN 

Automate Your Wheel Strategy on REGN

With Tiblio's Option Bot, you can configure your own wheel strategy including REGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol REGN
  • Rev/Share 135.2445
  • Book/Share 284.8611
  • PB 2.0998
  • Debt/Equity 0.0904
  • CurrentRatio 4.5976
  • ROIC 0.1047

 

  • MktCap 62310327200.0
  • FreeCF/Share 36.5804
  • PFCF 16.2072
  • PE 14.1001
  • Debt/Assets 0.0708
  • DivYield 0.0044
  • ROE 0.1511

 

  • Rating A
  • Score 4
  • Recommendation Buy
  • P/E Score 2
  • DCF Score 5
  • P/B Score 3
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation REGN Rothschild & Co Redburn -- Buy -- $890 Aug. 14, 2025
Downgrade REGN Argus Buy Hold -- -- June 30, 2025
Downgrade REGN Wells Fargo Overweight Equal Weight -- $580 May 30, 2025
Downgrade REGN RBC Capital Mkts Outperform Sector Perform -- $662 May 30, 2025
Upgrade REGN Citigroup Neutral Buy -- $700 May 14, 2025
Resumed REGN Cantor Fitzgerald -- Overweight -- $695 April 22, 2025
Upgrade REGN Leerink Partners Market Perform Outperform $762 $834 Feb. 5, 2025
Downgrade REGN UBS Buy Neutral $1130 $738 Jan. 16, 2025
Resumed REGN BofA Securities -- Underperform -- $565 Dec. 10, 2024
Downgrade REGN Leerink Partners Outperform Market Perform $1175 $1077 Sept. 24, 2024

News

A new pharma factory shows how hard it could be for drugmakers to outrun Trump's tariffs
JNJ, REGN
Published: August 21, 2025 by: CNBC
Sentiment: Positive

Fujifilm Biotechnologies will open a new biologics manufacturing plant in the U.S. this fall, with Regeneron and Johnson & Johnson as the initial customers. The Holly Springs, North Carolina, site is five years and $3.2 billion in the making.

Read More
image for news A new pharma factory shows how hard it could be for drugmakers to outrun Trump's tariffs
FDA Extends Review Period of REGN's Submission for Eylea HD
REGN
Published: August 21, 2025 by: Zacks Investment Research
Sentiment: Neutral

The FDA extends action dates for Regeneron's Eylea HD filings following inspection findings at Catalent Indiana. Nonetheless, Eylea HD remains available through vial administration.

Read More
image for news FDA Extends Review Period of REGN's Submission for Eylea HD
EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension
REGN
Published: August 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® (aflibercept) Injection 8 mg regulatory submissions. This includes a Chemistry, Manufacturing and Controls (CMC) Prior-Approval Supplement (PAS) for the EYLEA HD prefilled syringe and a supplemental Biologics License Application (sBLA) seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week (monthly) dosing across approved indications.

Read More
image for news EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension
Can Eylea HD and Dupixent Profits Revive Regeneron Stock?
REGN
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive

REGN banks on Dupixent and Eylea HD gains to offset Eylea's decline while oncology wins strengthen its diversified pipeline.

Read More
image for news Can Eylea HD and Dupixent Profits Revive Regeneron Stock?
Regeneron: EYLEA's Decline Is Masking A Deep Value Opportunity
REGN
Published: August 11, 2025 by: Seeking Alpha
Sentiment: Positive

Regeneron's Q2 showed strong earnings and cash flow, driven by DUPIXENT's growth and operational discipline, despite EYLEA's ongoing revenue decline. EYLEA faces intense competition and margin pressure, but DUPIXENT's expanding indications and LIBTAYO's solid performance offset these headwinds. Regeneron's oncology pipeline is advancing, highlighted by LYNOZYFIC's approval, while strategic moves in obesity drugs aim for future growth.

Read More
image for news Regeneron: EYLEA's Decline Is Masking A Deep Value Opportunity
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Call Transcript
REGN
Published: August 01, 2025 by: Seeking Alpha
Sentiment: Neutral

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ET Company Participants Christopher R. Fenimore - Executive VP of Finance & CFO George D.

Read More
image for news Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Call Transcript
Nonfarm Payrolls Come in SIgnificantly Below Expectations
CL, CVX, REGN, XOM
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Negative

Nonfarm Payrolls Come in SIgnificantly Below Expectations.

Read More
image for news Nonfarm Payrolls Come in SIgnificantly Below Expectations
Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
REGN
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive

REGN stock up as Q2 EPS jumps 12% on strong Eylea HD and Dupixent profits, beating revenue and earnings estimates.

Read More
image for news Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
Regeneron (REGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
REGN
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Read More
image for news Regeneron (REGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics
REGN
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive

Besides Wall Street's top-and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.

Read More
image for news Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics
5 Stocks That Launched New Dividends In This Roller-Coaster Market
MRP, REGN, VTOL, WDC, WSC
Published: July 29, 2025 by: Forbes
Sentiment: Positive

Brand new dividends are often the best divvies to buy. Here why.

Read More
image for news 5 Stocks That Launched New Dividends In This Roller-Coaster Market
Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
REGN
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive

Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
REGN
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive

Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.

Read More
image for news REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?
REGN
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Negative

Eylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.

Read More
image for news Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?
Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025
REGN
Published: July 10, 2025 by: Seeking Alpha
Sentiment: Positive

Regeneron Pharmaceuticals, Inc.'s stock continues to remain in the accumulation phase even after the setbacks associated primarily with itepekimab and Eylea. At the same time, Dupixent will remain Regeneron's key "cash cow" and its savior, the profit from sales of which will rise sharply in 2027. From its oncology franchise, I highlight Lynozyfic, which received its first FDA approval on July 2, and Libtayo, whose sales reached $285 million in Q1 2025.

Read More
image for news Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025
FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug
REGN
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive

REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.

Read More
image for news FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug
Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment
REGN
Published: July 02, 2025 by: WSJ
Sentiment: Positive

Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.

Read More
image for news Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment
US FDA approves Regeneron's blood cancer therapy
REGN
Published: July 02, 2025 by: Reuters
Sentiment: Positive

The U.S. Food and Drug Administration has approved Regeneron's cancer therapy, the company said on Wednesday, providing another treatment option for patients with a recurring and common form of blood cancer.

Read More
image for news US FDA approves Regeneron's blood cancer therapy
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
REGN, UTHR
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Read More
image for news Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade
REGN
Published: June 25, 2025 by: Seeking Alpha
Sentiment: Positive

Regeneron Pharmaceuticals, Inc. faces declining Eylea sales due to competition from Roche's Vabysmo and biosimilars like Amgen's Pavblu, but Dupixent's strong growth and new indications provide a robust near-term revenue driver. Libtayo and the oncology pipeline offer potential, but face tough competition and are unlikely to become blockbuster catalysts in the short term. The company's move into obesity drugs is a favorable development, with considerable potential from its experimental drug Trevogrumab, which shows promise in early trial data.

Read More
image for news Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade
Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid
REGN, SNY
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive

SNY and REGN's Dupixent gets FDA approval for a rare and chronic skin disease, marking its eighth approved indication for the drug.

Read More
image for news Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid
Regeneron CEO on 23andMe bid: Trying to balance individual privacy with biotech & genetics research
MEHCQ, REGN
Published: June 11, 2025 by: CNBC Television
Sentiment: Neutral

Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, privacy concerns over 23andMe's genetic data, importance of biotechnology, and more.

Read More
image for news Regeneron CEO on 23andMe bid: Trying to balance individual privacy with biotech & genetics research
Regeneron Pharmaceuticals, Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference Transcript
REGN
Published: June 09, 2025 by: Seeking Alpha
Sentiment: Neutral

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) 46th Annual Goldman Sachs Global Healthcare Conference June 9, 2025 10:40 AM ET Company Participants Christopher R. Fenimore - Executive VP of Finance & CFO Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Great.

Read More
image for news Regeneron Pharmaceuticals, Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference Transcript
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?
REGN
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive

REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline setbacks.

Read More
image for news REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?
Why Regeneron Is Falling And Why You Should Avoid It
REGN
Published: June 04, 2025 by: Benzinga
Sentiment: Negative

Regeneron Pharmaceuticals (REGN) has been in a persistent downtrend for over 280 days. The stock is currently in the 10th Phase of its 18-Phase Adhishthana Cycle, our proprietary cyclical framework.

Read More
image for news Why Regeneron Is Falling And Why You Should Avoid It
REGN Stock Undervalued At $500?
REGN
Published: June 02, 2025 by: Forbes
Sentiment: Negative

Regeneron Pharmaceuticals (NASDAQ:REGN) shares witnessed a notable 19% decline on Friday, May 30, in the wake of the unexpected failure of itepekimab, its chronic obstructive pulmonary disease (COPD) treatment in conjunction with Sanofi, during a late-stage clinical trial. One of the two trials did not achieve its primary endpoint, which is a significant setback considering that itepekimab was anticipated to become a blockbuster drug, with peak sales projections from Sanofi estimated between $2 billion and $6 billion.

Read More
image for news REGN Stock Undervalued At $500?
Regeneron's weight-loss drug helps preserve muscle mass in study
REGN
Published: June 02, 2025 by: Reuters
Sentiment: Positive

Regeneron Pharmaceuticals said on Monday its experimental weight-loss drug combination helped preserve muscle mass in a mid-stage study.

Read More
image for news Regeneron's weight-loss drug helps preserve muscle mass in study
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
REGN
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China

Read More
image for news Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
S&P 500 Gains & Losses Today: Ulta Beauty Stock Soars; Regeneron Shares Plummet
REGN, ULTA
Published: May 30, 2025 by: Investopedia
Sentiment: Neutral

Major U.S. equities indexes were mixed in the final session of the holiday-shortened trading week as President Donald Trump reverted to an antagonistic tone on trade with China and the latest Personal Consumption Expenditures data showed that inflation fell more than expected in April.

Read More
image for news S&P 500 Gains & Losses Today: Ulta Beauty Stock Soars; Regeneron Shares Plummet
Regeneron dashes Wall Street's hopes as COPD treatment trial suffers a failure
REGN
Published: May 30, 2025 by: Market Watch
Sentiment: Negative

Regeneron's stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result.

Read More
image for news Regeneron dashes Wall Street's hopes as COPD treatment trial suffers a failure

About Regeneron Pharmaceuticals, Inc. (REGN)

  • IPO Date 1991-04-02
  • Website https://www.regeneron.com
  • Industry Biotechnology
  • CEO Leonard S. Schleifer
  • Employees 15158

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.